Zyloprim

(Allopurinol)

ApprovedSmall molecule

Allopurinol is used to treat gout and kidney stones by reducing the amount of uric acid your body produces. It helps prevent painful gout attacks and complications from high uric acid levels.[2] Zyloprim is currently approved and in use across 59 indications[4].[1]

Zyloprim is one of 1179 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

156

Total Trials

Active Trials

1,178

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceActive, not recruiting

Coronary Artery DiseaseActive, not recruiting

Metabolic SyndromeActive, not recruiting

Cirrhosis of LiverApproved

Cardiovascular DiseaseApproved

Endothelial DysfunctionActive, not recruiting

Left Ventricular HypertrophyActive, not recruiting

Fetal Growth RestrictionActive, not recruiting

Essential HypertensionActive, not recruiting

ArthritisActive, not recruiting

Insulin ResistancePhase 2

Active, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Metabolic SyndromePhase 2

Active, not recruiting

Cirrhosis of LiverApproved

Approved

Cardiovascular DiseaseApproved

Approved

Endothelial DysfunctionApproved

Active, not recruiting

Left Ventricular HypertrophyApproved

Active, not recruiting

Fetal Growth RestrictionPreclinical

Active, not recruiting

Essential HypertensionPhase 2

Active, not recruiting

ArthritisPhase 1/Phase 2

Active, not recruiting

Showing 10 of 57 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zyloprim

Alnylam Pharmaceuticals

Approved

3 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Tafasitamab

Incyte

Preclinical

7 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Salt; Excess

NCT04026776

Q3 2027

Phase 3Recruiting

B Acute Lymphoblastic Leukemia

NCT03150693

Q4 2027

Phase 3Recruiting

Gout

NCT07089875

Phase 3Recruiting

Tophaceous Gout

NCT07089888

Q2 2028

Phase 2Recruiting

Chronic Lymphocytic Leukemia

NCT05536349

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia14 trials

Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

Completed· Takeda logo

Takeda·Phase 2·NCT01077284·99 enrolled

Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition

Completed·IIPCA Laboratories Ltd.·Phase 1·NCT01603134·32 enrolled

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Completed·GGoethe University·Phase 3·NCT00199043·80 enrolled

Show 11 more trials

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00061945·302 enrolled

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003700·163 enrolled

Busulfan and Cyclophosphamide Followed By ALLO BMT

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01685411·5 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Allopurinol Combination Study

Completed·AArdea Biosciences, Inc.·Phase 2·NCT01001338·227 enrolled

Combining Lesinurad With Allopurinol in Inadequate Responders

Completed·AArdea Biosciences, Inc.·Phase 3·NCT01510158·607 enrolled

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Completed·AArdea Biosciences, Inc.·Phase 1·NCT03272425·32 enrolled

Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

Unknown status·VVastra Gotaland Region·Phase 2·NCT03022747·60 enrolled

Combining Lesinurad With Allopurinol in Inadequate Responders

Completed·AArdea Biosciences, Inc.·Phase 3·NCT01493531·610 enrolled

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Completed·AArdea Biosciences, Inc.·Phase 1·NCT02581553·116 enrolled

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Completed·AArdea Biosciences, Inc.·Phase 1·NCT02888054·28 enrolled

Gout8 trials

Extension Study of ABP-671 in Participants With Gout

Terminated·AAtom Therapeutics Co., Ltd·Phase 2/3·NCT06276556·43 enrolled

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Completed·LLG Chem·Phase 3·NCT05586971·2,202 enrolled

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Recruiting·CCrystalys Therapeutics·Phase 3·NCT07089875·500 enrolled

Show 5 more trials

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

Completed·NNuon Therapeutics, Inc.·Phase 2·NCT01109121·112 enrolled

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Completed·AArdea Biosciences, Inc.·Phase 1·NCT02279641·12 enrolled

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Recruiting·MMassachusetts General Hospital·Phase 4·NCT04875702·650 enrolled

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

Completed· Takeda logo

Takeda·Phase 3·NCT00174915·1,072 enrolled

A Randomized, Open-Label, Multiple-Dose Phase II Study to Evaluate Efficacy and Safety of D-0120 Administered in Combination With Allopurinol in Subjects With Gout

Completed·IInventisBio Co., Ltd·Phase 2·NCT05665699·80 enrolled

Efficacy and Safety8 trials

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Completed· Novartis logo

Novartis·Phase 2·NCT00819585·432 enrolled

Zurig (Febuxostat) 40mg Efficacy and Safety Trial

Completed·GGetz Pharma·Phase 4·NCT02600780·50 enrolled

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

Completed· Regeneron logo

Regeneron·Phase 4·NCT01451645·82 enrolled

Show 5 more trials

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04956432·779 enrolled

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Completed· Gilead logo

Gilead·Phase 2·NCT02063997·248 enrolled

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Completed·AArthrosi Therapeutics·Phase 2·NCT05253833·42 enrolled

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04052932·594 enrolled

Efficacy and Safety of Oral Febuxostat in Participants With Gout

Completed· Takeda logo

Takeda·Phase 3·NCT00430248·2,269 enrolled

Heart Failure7 trials

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04327024·159 enrolled

Intravenous Allopurinol in Heart Failure

Completed·JJohns Hopkins University·Phase 2·NCT00181155·18 enrolled

Prednisone for Heart Failure Patients With Hyperuricemia

Completed·HHebei Medical University·Phase 2/3·NCT02129764·205 enrolled

Show 4 more trials

Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients

Completed·UUniversita di Verona·Phase 4·NCT00477789

Prednisone for Heart Failure Patients With Hyperuricemia

Completed·HHebei Medical University·Phase 4·NCT00919243·40 enrolled

Allopurinol in Chronic Heart Failure

Completed·NNational Heart and Lung Institute·Phase 4·NCT00997542·16 enrolled

Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

Completed·—·Phase 2·NCT00987415·253 enrolled

Hypertension5 trials

Uric Acid and Hypertension in African Americans

Completed·UUniversity of Florida·Phase 3·NCT00241839·150 enrolled

Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?

Completed·UUniversity of Dundee·Phase 4·NCT02237339·72 enrolled

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Recruiting·VVA Office of Research and Development·Phase 2·NCT05888233·50 enrolled

Show 2 more trials

Primary Prevention of Hypertension in Obese Adolescents

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00288158·60 enrolled

Allopurinol for Renal Transplant Associated Hypertension in Children

Withdrawn·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1/2·NCT00288171

83 more indications

Hyperuricemia4 trials

Genetics of Hyperuricemia Therapy in Hmong

Completed·UUniversity of Minnesota··NCT02371421·80 enrolled

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

Completed·NNuon Therapeutics, Inc.·Phase 2·NCT01052987·24 enrolled

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02078219·204 enrolled

Show 1 more trial

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

Completed·UUrica Therapeutics Inc.·Phase 1/2·NCT06056570·20 enrolled

Acute3 trials

Does Allopurinol Prolong a Treated, Acute Gout Flare?

Completed·559th Medical Wing·Phase 4·NCT01988402·35 enrolled

Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout

Completed·WWhite River Junction Veterans Affairs Medical Center·Phase 4·NCT01310673·57 enrolled

Allopurinol in Acute Gout

Withdrawn·UUniversité de Sherbrooke·N/A·NCT01775098

Trial3 trials

Rasburicase (Fasturtec) Registration Trial

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00607152·10 enrolled

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

Completed· Takeda logo

Takeda·Phase 3·NCT00102440·760 enrolled

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

Completed· Takeda logo

Takeda·Phase 3·NCT00175019·1,086 enrolled

Lymphoma3 trials

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000658·250 enrolled

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02953509·178 enrolled

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000703·45 enrolled

Tics3 trials

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03836599·6 enrolled

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

Completed·UUniversity of California, San Francisco·Phase 4·NCT02956278·27 enrolled

Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04532918·14 enrolled

Tumor Lysis Syndrome3 trials

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01200485·55 enrolled

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Completed· Menarini logo

Menarini·Phase 3·NCT01724528·346 enrolled

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Completed· Sanofi logo

Sanofi·Phase 3·NCT00230178·280 enrolled

Uric Acid3 trials

Gender Differences in the Metabolic Effects of Uric Acid

Withdrawn·UUniversity of Missouri-Columbia·Phase 1·NCT03076684

Uric Acid and the Endothelium in CKD

Completed·UUniversity of Colorado, Denver·N/A·NCT01228903·80 enrolled

Lowering Uric Acid in Live Kidney Donors

Completed·OOslo University Hospital·Phase 2·NCT03353298·71 enrolled

Safety and Efficacy3 trials

Safety and Efficacy of Oral Febuxostat in Subjects With Gout

Completed·XXijing Hospital·Phase 3·NCT02082769·504 enrolled

A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

Completed· Astellas logo

Astellas·Phase 3·NCT01736514·109 enrolled

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

Terminated· Regeneron logo

Regeneron·Phase 3·NCT01459796·220 enrolled

Cirrhosis3 trials

Allopurinol and Quality of Life in Liver Cirrhosis

Completed·TTanta University·Phase 2/3·NCT05828836·100 enrolled

Allopurinol and Pathogenesis of Cirrhosis

Completed·TTanta University·Phase 1/2·NCT07033533·100 enrolled

Allopurinol to Prevent Cirrhosis Related Morbidities

Completed·TTanta University·Phase 2/3·NCT05545670·100 enrolled

Acute Kidney Injury2 trials

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

Unknown status·IInstituto Nacional de Cardiologia Ignacio Chavez·Phase 2·NCT03767322·558 enrolled

Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients

Unknown status·—·Phase 4·NCT05540184·124 enrolled

Chronic Kidney Disease2 trials

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03990363·861 enrolled

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Terminated·VVirginia Commonwealth University·Phase 2·NCT03865407·17 enrolled

Type 1 Diabetes2 trials

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

Completed·AAlessandro Doria·Phase 3·NCT02017171·530 enrolled

Microalbuminuria and Allopurinol in Type 1 Diabetes

Completed·PPeter Rossing·Phase 4·NCT02829177·30 enrolled

Left Ventricular Hypertrophy2 trials

Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study

Completed·UUniversity of Dundee·Phase 4·NCT01951404·80 enrolled

Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

Completed·AA. D. Struthers·Phase 4·NCT00688480·67 enrolled

Acute Coronary Syndrome2 trials

Allopurinol in Acute Coronary Syndrome

Terminated·SStephen McSwiggan·Phase 4·NCT01457820·26 enrolled

Allopurinol in Acute Coronary Syndrome

Completed·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT03745729·162 enrolled

Endothelial Function2 trials

APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X

Completed·UUniversity of Dundee·Phase 4·NCT00512057·40 enrolled

Allopurinol and Endothelial Function in Diabetic CAD Patients

Unknown status·UUniversity Tunis El Manar·N/A·NCT03385135·58 enrolled

Efficacy2 trials

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

Completed· Gilead logo

Gilead·Phase 2·NCT01399008·100 enrolled

Efficacy of Allopurinol and Dypiridamole in Acute Mania

Completed·—·Phase 4·NCT00560079·180 enrolled

Phase 22 trials

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Completed·AAtom Therapeutics Co., Ltd·Phase 2/3·NCT05818085·300 enrolled

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Completed·AArdea Biosciences, Inc.·Phase 2·NCT02498652·41 enrolled

Obstructive Sleep Apnea2 trials

Study of Cardiovascular Disease and Obstructive Sleep Apnea

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01637623·87 enrolled

Vascular Pathophysiology in Obstructive Sleep Apnea

Withdrawn·UUniversity of Wisconsin, Madison·N/A·NCT00214084

Dilated Cardiomyopathy2 trials

Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy

Withdrawn·UUniversity of Pennsylvania·Phase 1/2·NCT00281255

Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy

Unknown status·—··NCT05193838·100 enrolled

Chronic Lymphocytic Leukemia2 trials

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00899431·39 enrolled

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05536349·60 enrolled

Impairment1 trial

Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'

Completed·UUniversity of Dundee·Phase 4·NCT01550107·124 enrolled

Pancreatitis1 trial

Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Completed·—·N/A·NCT02992652·100 enrolled

Tophaceous Gout1 trial

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Recruiting·CCrystalys Therapeutics·Phase 3·NCT07089888·250 enrolled

Hand-foot syndrome1 trial

Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT01609166·60 enrolled

Coronary Artery Disease1 trial

Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 4·NCT03700645·100 enrolled

Small Cell Lung Cancer1 trial

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Terminated·WWashington University School of Medicine·Phase 1·NCT05049863·17 enrolled

Excretion1 trial

Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

Completed·LLandspitali University Hospital·Phase 4·NCT02752633·9 enrolled

Cutaneous Leishmaniasis1 trial

Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00004755·375 enrolled

Local1 trial

The Effect of Antioxidants on Skin Blood Flow During Local Heating

Completed·TThe University of Texas at Arlington·Phase 1·NCT03680638·44 enrolled

Dialysis Patients1 trial

Optimal Administration of Allopurinol in Dialysis Patients

Completed·MMaisonneuve-Rosemont Hospital·Phase 4·NCT02477488·50 enrolled

Prevention1 trial

Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.

Completed·IInstituto de Investigacion Sanitaria La Fe·Phase 3·NCT01987570·53 enrolled

Growth1 trial

Antenatal Allopurinol in Intrauterine Growth Restriction

Unknown status·UUMC Utrecht·N/A·NCT00346463·50 enrolled

Multiple Myeloma1 trial

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Unknown status·SSwedish Medical Center·Phase 2·NCT03570983·100 enrolled

Bipolar Disorder1 trial

Allopurinol Maintenance Study for Bipolar Disorder

Terminated·—·Phase 4·NCT00732251·15 enrolled

Brain Injury1 trial

Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome

Unknown status·UUniversity Hospital Tuebingen·Phase 3·NCT03162653·760 enrolled

Hematologic Malignancies1 trial

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT01564277·24 enrolled

Interaction1 trial

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

Completed·BBioCryst Pharmaceuticals·Phase 2·NCT01129648·87 enrolled

Refractory1 trial

Allopurinol Add-on Treatment for Refractory Mania

Completed·—·Phase 4·NCT00643123·40 enrolled

Arthritis1 trial

Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis

Unknown status·SShifa Ul Mulk Memorial Hospital·Phase 1/2·NCT03506919·200 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

Completed·—··NCT04746989·294,878 enrolled

Vitamin D1 trial

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

Completed·—·Phase 3·NCT01320722·242 enrolled

Stem Cell Transplant1 trial

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053196·82 enrolled

Congenital Heart Disease1 trial

Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

Recruiting·Ddr. M.J.N.L. Benders·Phase 3·NCT04217421·236 enrolled

Essential Hypertension1 trial

Uric Acid in Essential Hypertension in Children

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00288184·30 enrolled

Cardiovascular1 trial

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Completed· Takeda logo

Takeda·Phase 3·NCT01101035·6,198 enrolled

Antipsychotics1 trial

Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode

Completed·SSheba Medical Center·Phase 3·NCT01092221·180 enrolled

Arterial Stiffness1 trial

Completed·UUniversity of Missouri-Columbia·Phase 2·NCT03648996·34 enrolled

Refractory Angina1 trial

Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms

Unknown status·MMinistry of Health, Brazil·Phase 2/3·NCT04368819·40 enrolled

Metabolism1 trial

Effect of Allopurinol on Markers of Mineral and Bone Metabolism

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT05601271·50 enrolled

Diabetes1 trial

Impact of Diabetes on Left Ventricular Remodeling

Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT01052272·72 enrolled

Hematological Diseases1 trial

Allo HSCT Using RIC for Hematological Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02661035·156 enrolled

Treatment1 trial

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

Unknown status·HHillel Yaffe Medical Center·N/A·NCT03601260·700 enrolled

Skin1 trial

The Effect of Antioxidants on Skin Blood Flow-BH4

Completed·TThe University of Texas at Arlington·Phase 1·NCT03680573·16 enrolled

Adenylosuccinate Lyase Deficiency1 trial

Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03776656·8 enrolled

Kidney1 trial

ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS

Completed·—·N/A·NCT07177898·80 enrolled

Clinical Trial1 trial

Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial

Completed·MMaimónides Biomedical Research Institute of Córdoba·Phase 2·NCT04983160·22 enrolled

Graft Versus Host Disease1 trial

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Completed·MMassachusetts General Hospital·Phase 1·NCT00513474·46 enrolled

Outcome1 trial

Allopurinol Outcome Study

Completed·AArdea Biosciences, Inc.·Phase 4·NCT01391325·1,735 enrolled

Complication1 trial

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

Unknown status·TTanta University·Phase 2/3·NCT05511766·150 enrolled

Drug1 trial

A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04550234·25 enrolled

Cardiovascular Events1 trial

The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

Recruiting·PPoznan University of Medical Sciences·Phase 3·NCT05943821·1,116 enrolled

Effectiveness1 trial

HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness

Not yet recruiting·HHaiphong University of Medicine and Pharmacy·Phase 4·NCT07369622·228 enrolled

Kidney Stone1 trial

Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL

Completed·SSanglah General Hospital·Phase 4·NCT05414669·35 enrolled

Aspirin1 trial

Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT03195153·200 enrolled

Peripheral Arterial Disease1 trial

Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease

Completed·UUniversity of Dundee·Phase 4·NCT01147705·50 enrolled

Heart1 trial

A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04256629·24 enrolled

Metabolic Syndrome1 trial

Hyperuricemia on Hypertension and Metabolic Syndrome

Completed·IInstituto Nacional de Cardiologia Ignacio Chavez·Phase 2·NCT01157936·40 enrolled

Stroke1 trial

XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke

Completed·NNHS Greater Glasgow and Clyde·Phase 4·NCT02122718·464 enrolled

Tuberculosis1 trial

Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers

Completed·NNational University Hospital, Singapore·Phase 1·NCT02700347·12 enrolled

IgA Nephropathy1 trial

A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

Completed·SSun Yat-sen University·N/A·NCT00793585·40 enrolled

Insulin resistance1 trial

The Effect of Allopurinol on Insulin Resistance and Blood Pressure

Completed·—·Phase 2·NCT00639756·60 enrolled

Leukemia1 trial

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00039130·105 enrolled

Pediatric ALL1 trial

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02046694·34 enrolled

Schizophrenia1 trial

Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia

Completed·SSheba Medical Center·Phase 4·NCT00864825·248 enrolled

Hematologic Cancer1 trial

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00602693·41 enrolled

Ovarian Cancer1 trial

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00652899·14 enrolled

Refractory AML1 trial

T-Cell Depleted Double UCB for Refractory AML

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01464359·3 enrolled

Endothelial Dysfunction1 trial

Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines

Unknown status·GGuangzhou General Hospital of Guangzhou Military Command·Phase 4·NCT02797028·320 enrolled

Chronic Renal Failure1 trial

The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure

Completed·IIstanbul University·N/A·NCT00978653·20 enrolled

Acute Myelogenous Leukemia1 trial

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT05805605·56 enrolled

B Acute Lymphoblastic Leukemia1 trial

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT03150693·303 enrolled

Salt; Excess1 trial

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

Recruiting·WWake Forest University Health Sciences·Phase 1·NCT04026776·120 enrolled

Unspecified2 trials

Center of Research Translation (CORT) Project 2

Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT02038179·99 enrolled

PERL Continuous Glucose Monitoring (CGM) Study

Completed·JJoslin Diabetes Center··NCT03334318·175 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

LOPURIN

NDA NDA018297

Jan 1, 1982

ZYLOPRIM

NDA NDA016084

Sep 28, 1984

ALLOPURINOL

NDA NDA018785

Sep 28, 1984

ALLOPURINOL

NDA NDA018832

Sep 28, 1984

ALLOPURINOL

NDA NDA018877

Nov 16, 1984

ALLOPURINOL

NDA NDA018241

May 17, 1996

ALOPRIM

NDA NDA020298

Sources

References

[1]
ClinicalTrials.gov — 156 trial records for Allopurinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Zyloprim drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Allopurinol compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Allopurinol. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020298). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Xanthine Dehydrogenase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Alnylam Pharmaceuticals